Annovis Bio Inc (NYSE:ANVS)’s traded shares stood at 0.35 million during the last session, with the company’s beta value hitting 1.74. At the close of trading, the stock’s price was $9.69, to imply an increase of 5.44% or $0.5 in intraday trading. The ANVS share’s 52-week high remains $22.49, putting it -132.09% down since that peak but still an impressive 53.25% since price per share fell to its 52-week low of $4.53. The company has a valuation of $126.45M, with an average of 0.26 million shares in intraday trading volume over the past 10 days and average of 1.76 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Annovis Bio Inc (ANVS), translating to a mean rating of 1.33. Of 2 analyst(s) looking at the stock, 0 analyst(s) give ANVS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.49.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Annovis Bio Inc (NYSE:ANVS) trade information
After registering a 5.44% upside in the last session, Annovis Bio Inc (ANVS) has traded red over the past five days. The 5-day price performance for the stock is 13.60%, and -7.45% over 30 days. With these gigs, the year-to-date price performance is -48.18%. Short interest in Annovis Bio Inc (NYSE:ANVS) saw shorts transact 1.48 million shares and set a 0.32 days time to cover.
The extremes give us $21 and $26 for target low and target high price respectively. As such, ANVS has been trading -168.32% off suggested target high and -116.72% from its likely low.
Annovis Bio Inc (ANVS) estimates and forecasts
Looking at statistics comparing Annovis Bio Inc share performance against respective industry, we note that the company has outperformed competitors. Annovis Bio Inc (ANVS) shares are -2.52% down over the last 6 months, with its year-to-date growth rate higher than industry average at 48.58% against 18.60%. Revenue is forecast to grow 69.90% this quarter before jumping 83.50% for the next one.
ANVS Dividends
Annovis Bio Inc has its next earnings report out in September. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Annovis Bio Inc (NYSE:ANVS)’s Major holders
Annovis Bio Inc insiders hold 21.56% of total outstanding shares, with institutional holders owning 8.11% of the shares at 10.34% float percentage. In total, 8.11% institutions holds shares in the company, led by LMR PARTNERS LLP. As of 2024-06-30, the company held over 0.57 million shares (or 5.3844% of shares), all amounting to roughly $3.3 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 0.36 million shares, or about 3.401% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $2.08 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Annovis Bio Inc (ANVS) shares. Going by data provided on Mar 31, 2024 , Vanguard Total Stock Market Index Fund holds roughly 239.51 shares. This is just over 1.83% of the total shares, with a market valuation of $2.32 million. Data from the same date shows that the other fund manager holds a little less at 101.3, or 0.78% of the shares, all valued at about 0.98 million.
